In a cohort study, Kamyar Kalantar-Zadeh, MD, PhD, of the University of California Irvine, and colleagues studied 108,635 MHD patients followed for up to 5 years. The cohort had a mean age of 64 years. The composition of the cohort was 59% diabetic, 45% women, and 33% black.
Compared with patients who had a serum phosphorus level of 7.0 mg/dL or higher and a normalized protein catabolic rate (nPCR)—a surrogate of dietary protein intake—below 0.8 g/kg/day, patients with a serum phosphorus level of at least 3.5 but less than 5.5 mg/dL and an nPCR of at least 1 but less than 1.2 g/kg/day had the greatest survival: a 51% decreased risk of death in a fully adjusted model.
Continue Reading
The researchers noted that their results are limited by the lack data on protein binders.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.